Transplantation of Autologous Peripheral Blood Progenitor Cells Procured after High-Dose Cytarabine-Based Consolidation Chemotherapy for Adults with Secondary Acute Myelogenous Leukemia in first Remission

References

• Curtis J E, Messner H A, Minden M D, Minken S, McCulloch E A. High‐dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes. J Clin Oncol 1987; 5: 532–534
   PubMed Web of Science ®Google Scholar
• Schiller G, Gajewski J, Temto M, Nimer S, Lee M, Belin T, Champlin R. Long‐term outcome of high‐dose cytara‐bine‐based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 977–2982
   Google Scholar
• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, Omura G A, Moor J O, McIntyre O R, Frei E B, Cancer and Leukemia Group. Intensive post‐remission chemotherapy in adults with acute myeloid leukemia. New England J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Preisler H D, Raza A, Early A, Kirshner J, Brecher M, Freeman A, Rustum Y, Azamia N, Priore R, Sandberg A, Bloch A M, Browman G, Walker I, Benjer A, Miller K, D'Arrigo D, Doeblin T, Stein A, Bloom M, Logue G, Rustat P, Barcos M, Laron R, Joyce R. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987; 5: 722–730
   PubMed Web of Science ®Google Scholar
• Rai K R, Holland J F, Glidewell O J, Weinberg V, Brunner K, Obrecht J P, Preisler H D, Nawabi I W, Prager D, Carey R W, Cooper M R, Hanrani F, Hutchinson J L, Silver R T, Falkson G, Wiernik P, Hoagland H C, Bloomfield C D, James C W, Gottlieb A, Ramanan S V, Blom J, Nissen N I, Bank H, Ellison R R, Kung F, Henry P, McIntyre O R, Kaan S K. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981; 58: 1203–1212
   PubMed Web of Science ®Google Scholar
• Preisler H D, Raza A, Barcos M, Azamia N, Larson R, Walker I, Browman M, Grunwald H, D'Amgo P, Doeblin T, Bloom M, Stein A, Logue G, Goldberg J, Kirshner J, Gottlieb A, Bennett J. High‐dose cytosine arabinoside as the initial treatment of poor‐risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup study. J Clin Oncol 1987; 5: 75–82
   PubMed Web of Science ®Google Scholar
• Fenaux P, Morel P, Rose C, Lai J L, Jouet J P, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J Haematol 1991; 77: 497–501
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Estey E H, Keating M J. Treatment of therapy‐related leukemia and myelodysplastic syndrome. Advanced in the Management of Adult Acute Leukemia, C D Bloomfield, G P Herzig. WB Saunders Co, Philadelphia 1993; 81–107
   Google Scholar
• Keating M J, McCredie K B, Benjamin R S, Bodey G P, Zander A, Smith T L, Freireich E J. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincris‐tine, and prednisone (ROAP). Blood 1981; 58: 584–591
   PubMed Web of Science ®Google Scholar
• Gajewski J L, Ho W G, Nimer S D, Hirji K F, Gekelman L, Jacobs A D, Champlin R E. Efficacy of intensive chemotherapy for acute myelogenous leukaemia associated with a preleukaemic syndrome. J Clin Oncol 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A. Allo‐geneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Worlung Party of the European Bone Marrow Transplantation Group. Br J Haematol 1990; 74: 151–155
   PubMed Web of Science ®Google Scholar
• Runde V, de Witte T, Aul C, Gratwohl A, Niederwieser D, van Biezen A, Hermans J, Vemant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Arnold R, Cahn J, van Lint M, Verdonk L, Apperley J. Myelodysplastic syndromes (MDS) or leukemia following MDS (sAML) treated with allogeneic bone marrow transplantation (BMT): a survey of the working party on chronic leukemia of the EBMT. Ann Hematol 1995; 70(suppl. 11)A138
   Google Scholar
• Ganser A, Heil G, Kolbe K, Maschmeyer G, Fischer J T, Bergmann L, Mitrou P S, Heit W, Heimpel H, Huber C, Hoe‐lzer D. Aggressive chemotherapy combined with G‐CSF and maintenance therapy with interleukin‐2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia ‐ initial results. Ann Hematol 1993; 66: 123–125
   PubMed Web of Science ®Google Scholar
• Gardin C, Chaibi P, de Revel T, Rousselot P, Turlure P, Miclba J M, Nédellec G. Dombret H for the Club de Reflexion en Hémotologie Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony‐stimulating factor (G‐CSF) in patients with secondary and therapy‐related acute myelogenous leukemia. Leukemia 1997; 11: 16–21
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L. A controlled study of recombinant human granulocyte colony‐stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New Engl J Med 1995; 332: 1678–1683
   PubMed Web of Science ®Google Scholar
• Suciu S, Kuse R, Weh H J, Hossfeld D K. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990; 44: 15–26
   PubMed Web of Science ®Google Scholar
• Estey E H, Kantarjian H M, O'Brien S, Komblau S, Andreef M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory ane‐mia with excess blasts (RAEB) in transformation (RAEB‐t) given acute myelogenous leukemia (AML)‐type chemotherapy in combination with granulocyte CSF (G‐CSF). Cyto Mol Ther 1995; 1: 21–28
   PubMedGoogle Scholar
• Guerci A, Merlin J L, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular dauno‐rubicin accumulation and P‐Glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85(8)2147–2153
   PubMed Web of Science ®Google Scholar
• Berman E, Little C, Gee T, O'Reilly R, Clarkson B. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. New Engl J Med 1992; 326: 156–160
   PubMed Web of Science ®Google Scholar
• De Witte T, Suciu S, Boogaerts M, Labar B, Archimbaud E, Runde V, Selleslag D, Zittoun R, van der Lelie J, Muus P, DeMuynck H, Dardenne M, Willemze R, Gratwohl A, Apperley J. Intensive remission‐induction chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients < 60 years. A joint study of the EORTC LCG and the EBMT. Blood 1995; 86(suppl. 1)618a
   Google Scholar
• Scbiller G, Lee M, Lill M, Mittal‐Henkle A, Paquette R, Sawyers C, Territo M. Transplantation of autologous peripheral blood progenitor cells procured after high‐dose cytarabine‐based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission. Leukemia 1997; 11: 1533–1539
   PubMed Web of Science ®Google Scholar
• Stein A S, O'Donnell M R, Chai A, Schmidt G M, Nademanee A, Parker P M, Smith E P, Snyder D S, Molina A, Stepan D E, Spielberger R, Somlo G, Margolin K A, Vora N, Lipsett J, Lee J, Niland J, Forman S J. In vivo purging with high‐dose cytarabine followed by high‐dose chemoradiotber‐apy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996; 14: 2206–2216
   PubMed Web of Science ®Google Scholar
• Gorin N C, Aegerter P, Auvert B, Meloni G, Goldstone A H, Bumett A, Carella A, Korbling M, Herve P, Maraninchi D, Lowenberg R, Verdonck L F, De Plangin M, Hermans J, Hel‐big W, Porcellini A, Rizzoli V, Alexandrino E P, Franklin I M, Reiffers J, Colleselli P, Goldman J M. Autologous bone marrow transplantation for acute niyelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–1614
   PubMed Web of Science ®Google Scholar
• Sanz M A, de la Rubia J, Sanz G F, Martin G, Martinez J, Jarque I, Sempere A, Gomis F, Senent L, Soler M A, Lopez F, Arilla M J, Carpio N, Guinot M, Palau J, Tudela M, Marty M L. Busulfan plus cyclophosphamide followed by autologous blood stem‐cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993; 11: 1661–1667
   PubMed Web of Science ®Google Scholar
• Laporte J PH, Douay L, Lopez M, Labopin M, Jouet J P, Lesage S, Stachowiak J, Fouillard L, Isnard F, Noel‐Walter M P, Pene F, Deloux J, Van Den Akker J, Grande M, Bautes F, Najman A, Gorin N C. One hundred twenty‐five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10‐year single institution experience. Blood 1994; 84: 3810–3818
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D M, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposals for the classification of acute leukaemias. French‐American‐British (FAB) co‐operative group. Br J Haematol 1977; 33: 451–458
   Web of Science ®Google Scholar
• Schiller G J, Nimer S D, Territo M C, Ho W G, Champlin R E, Gajewski J L. Bone marrow transplantation versus high‐dose cytarabine‐based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992; 10: 41–46
   PubMed Web of Science ®Google Scholar
• Ellison R R, Holland J F, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver R T, Karanas A, Cuttner J, Spurr C L, Hayes D M, Blom J, Leone L A, Hau‐rani F, Kyle R, Hutchinson J L, Forcier J, Moon J H. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstratten B, Staquet M, Winkler A. Reporting results of' cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Sun G, Koeffler H P, Gale R P, Sparkes R S, Schrech R R. Use of conditioned media in cell culture can mask cytogenetic abnormalities in acute leukemia. Cancer Genet Cytogenet 1990; 46: 107–114
   PubMed Web of Science ®Google Scholar
• Verma R S, Babu A. Human Chromosomes: Manual of Basic Technique. Pergamon Press, New York 1989
   Google Scholar
• Winston D J, Ho W G, Bruckner D A, Champlin R E. Beta‐lac‐tam antibiotic therapy in febrile granulocytopenic patients A randomized trial comparing cefoperazone plus pip‐eracillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115: 849–859
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• BMDP Program in the Biomedical Sciences, W J Dixon. University of California Press, Los Angeles 1983
   Google Scholar
• De Witte T, Suciu S, Verhoef G, Lahar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadon S, Jehn U, Muus P, DeMuynck H, Dardenne M, Zittoun R, Willenze R, Gratwohl A, Apperley J. Autologous stem cell transplantation for patients with poor risk MDS and secondary AML (sAML). A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups. Blood 1997; 90(suppl. 1)583a
   Google Scholar
• De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri S B, Carella A, Apperley J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 1997; 90(10)3853–3857
   PubMed Web of Science ®Google Scholar
• De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, et al. Intensive chemotherapy for poor prognosis myelo‐dysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration, A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC‐LCG). Leukemia 1995; 9(11)1805–1811
   PubMed Web of Science ®Google Scholar
• De Witte T. New treatment approaches for myelodysplastic syndrome and secondary leukaemias. Ann of Oncol 1994; 5(5)401–408
   PubMed Web of Science ®Google Scholar
• De Witte T, Zwaan F, Hermans J, Vemant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A, Working Party on Leukaemia, European Cooperative Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J of Haematol 1990; 74: 151–155
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Estey E H, Keating M J. Treatment of therapy‐related leukemia and myelodysplastic syndrome. Hematol/Onc Clinics of N Am 1993; 7(1)81–107
   PubMed Web of Science ®Google Scholar